When the price of serplulimab was decreased by 66%, 69% and 61%, respectively, the ICERs of serplulimab plus chemotherapy versus chemotherapy were lower than the WTP thresholds for advanced ESCC patients with PD-L1-positive, PD-L1 1 ≤ CPS < 10 and CPS ≥ 10 (Figure 2). The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.